Airsculpt Technologies, Inc. (AIRS)
NASDAQ:AIRS
Top Page
Airsculpt Technologies
(NASDAQ:AIRS)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-29.97% Downside)
Action:ReiteratedDate:04/02/26
The score is held down primarily by deteriorated financial performance (declining revenue, compressed margins, and sustained losses) and weaker/volatile cash generation, despite improved leverage. Technicals show some near-term stabilization but a still-weak longer-term trend. The earnings call suggests an early-stage turnaround with conservative 2026 guidance, but liquidity, refinancing, operational execution, supply risk, and control issues keep risk elevated.
Positive Factors
Proprietary Procedure & Clinic Network
AirSculpt's proprietary minimally invasive procedure combined with a company-owned clinic footprint creates durable competitive advantages: control of patient experience, pricing power for elective services, and the ability to capture higher clinic-level margins. Historical gross margins in prior years support resilient unit economics as volume recovers.
Negative Factors
Sustained Revenue Decline
Two consecutive years of declining revenue compress operating leverage and strain profitability in a model reliant on elective, out-of-pocket procedures. Persistent top-line weakness reduces the margin of safety for fixed clinic costs and makes recovery dependent on durable demand improvement and successful service expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary Procedure & Clinic Network
AirSculpt's proprietary minimally invasive procedure combined with a company-owned clinic footprint creates durable competitive advantages: control of patient experience, pricing power for elective services, and the ability to capture higher clinic-level margins. Historical gross margins in prior years support resilient unit economics as volume recovers.
Read all positive factors
Airsculpt Technologies (AIRS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$186.24M
Dividend YieldN/A
Average Volume (3M)1.05M
Price to Earnings (P/E)23.3
Beta (1Y)2.35
Revenue Growth-16.54%
EPS Growth-119.56%
CountryUS
Employees389
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-0.02
Shares Outstanding70,545,685
10 Day Avg. Volume629,231
30 Day Avg. Volume1,053,493
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.36
Price to Sales (P/S)0.79
P/FCF Ratio172.97
Enterprise Value/Market Cap1.40
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit2.71
Enterprise Value/Ebitda56.58
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$153.25M
Airsculpt Technologies Business Overview & Revenue Model
Company Description
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using i...
How the Company Makes Money
AirSculpt Technologies makes money primarily by charging patients for elective, out-of-pocket aesthetic procedures performed at its company-owned centers. The company’s key revenue stream is procedure revenue from AirSculpt body contouring; it als...
Airsculpt Technologies Earnings Call Summary
Earnings Call Date:Apr 06, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 08, 2026
Earnings Call Sentiment Neutral
The call highlights a company in active turnaround: operational actions (cost savings, debt reduction, marketing enhancements) have produced Q4 margin expansion, improved same-store sales trends and early traction with new services (skin tightening and skin removal). However, material revenue declines in 2025, weaker full-year adjusted EBITDA versus 2024, a sharp drop in operating cash flow, modest year-end cash, supply risk for key equipment and a reporting control matter temper the progress. Management’s 2026 guidance is conservative and back‑end loaded, reflecting improving momentum but ongoing execution and liquidity risks.Positive Updates
Sequential Same-Store Sales Improvement and Positive Inflection
Same-store sales improved materially over the year, moving from down ~22% at the start of 2025 to positive in February 2026; March trends continued favorably and Q1 2026 same-store sales are expected to be flat (midpoint of prior revenue range).
Negative Updates
Revenue Declines – Q4 and Full Year
Q4 revenue of $33.4M, down ~15% year-over-year; same-store revenue declined ~16% in Q4. Fiscal 2025 revenue was $151.8M, down approximately 15.8% versus fiscal 2024.
Read all updates
Q4-2025 Updates
Positive
Negative
Sequential Same-Store Sales Improvement and Positive Inflection
Same-store sales improved materially over the year, moving from down ~22% at the start of 2025 to positive in February 2026; March trends continued favorably and Q1 2026 same-store sales are expected to be flat (midpoint of prior revenue range).
Read all positive updates
Company Guidance
AirSculpt guided 2026 revenue of $151 million to $157 million (midpoint implying ~3% comparable growth ex‑London, with London having contributed ~1% to 2025 comps), and adjusted EBITDA of $15 million to $17 million; they expect Q1 same‑store sales to be flat (the midpoint of their prior revenue range) with momentum building through the year after comps turned positive in Feb and continued into March. The outlook incorporates the annualization of their 25 cost actions (and some portion of the ~$4 million in 2025 annualized savings will be reinvested in growth), assumes no de‑novo openings this year, and reflects a balance‑sheet focus — targeting net debt leverage below 2.5x and a term‑loan refinance (year‑end 2025 cash was $8.4 million, gross debt $56 million after $19 million of 2025 paydowns, over $30 million repaid in the last five quarters, plus an additional $14.8 million raised via ATM and $11 million of further paydowns in Q1).Airsculpt Technologies Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
58
Neutral
Cash Flow
41
Neutral
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 151.82M | 180.35M | 195.92M | 168.79M | 133.31M |
| Gross Profit | 90.13M | 108.97M | 121.91M | 110.51M | 88.78M |
| EBITDA | 1.22M | 10.07M | 19.74M | 4.59M | 22.36M |
| Net Income | -11.67M | -8.25M | -4.48M | -14.68M | 10.55M |
Balance Sheet | |||||
| Total Assets | 187.30M | 210.00M | 204.02M | 200.76M | 200.55M |
| Cash, Cash Equivalents and Short-Term Investments | 8.45M | 8.23M | 10.26M | 9.62M | 25.35M |
| Total Debt | 83.57M | 105.05M | 99.67M | 107.65M | 100.58M |
| Total Liabilities | 99.59M | 130.71M | 120.03M | 129.99M | 117.03M |
| Stockholders Equity | 87.71M | 79.29M | 83.99M | 70.77M | 83.53M |
Cash Flow | |||||
| Free Cash Flow | 692.00K | -2.66M | 14.04M | 11.53M | 19.52M |
| Operating Cash Flow | 3.10M | 11.35M | 23.96M | 24.45M | 26.63M |
| Investing Cash Flow | -2.40M | -14.01M | -9.92M | -12.92M | -7.12M |
| Financing Cash Flow | -478.00K | 630.00K | -13.39M | -27.26M | -4.55M |
Airsculpt Technologies Technical Analysis
Negative
3.57
Price Trends
2.34
Positive
2.59
Positive
4.83
Negative
Market Momentum
0.14
Positive
49.84
Neutral
23.87
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIRS, the sentiment is Negative. The current price of 3.57 is above the 20-day moving average (MA) of 2.79, above the 50-day MA of 2.34, and below the 200-day MA of 4.83, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 23.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIRS.
Airsculpt Technologies Risk Analysis
Airsculpt Technologies disclosed 74 risk factors in its most recent earnings report. Airsculpt Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Airsculpt Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.66B | 17.67 | 11.57% | 1.80% | 23.74% | -18.99% | |
73 Outperform | $1.37B | 23.43 | 11.83% | ― | 6.26% | -19.33% | |
56 Neutral | $436.67M | 0.82 | -31.57% | ― | 0.74% | ― | |
54 Neutral | $306.38M | -0.79 | -24.30% | ― | -22.14% | -787.87% | |
52 Neutral | $690.52M | -6.34 | -14.67% | ― | -11.42% | -617.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $186.24M | 23.32 | -13.79% | ― | -16.54% | -119.56% |
* Healthcare Sector Average
AIRS
Airsculpt Technologies
2.64
0.86
48.31%
AMN
AMN Healthcare Services
17.87
-1.87
-9.47%
CYH
Community Health
3.15
0.57
22.09%
CCRN
Cross Country Healthcare
9.48
-4.90
-34.08%
HCSG
Healthcare Services
19.49
9.70
99.08%
NHC
National Healthcare
170.85
80.33
88.74%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.